Aditya Bardia, MD, MPH
Accepting New Patients

Aditya Bardia, MD, MPH

  • Hematology Oncology
Average rating: 5.0
 
Santa Monica Parkside Cancer Care |

About

Program Director, Breast Medical Oncology, 
Assistant Chief (Translational Research), Division of Hematology-Oncology, 
Professor of Medicine, Geffen School of Medicine, University of California Los Angeles,   
Director of Translational Research Integration, UCLA Health Jonsson Comprehensive Cancer Center,  
 

Languages

English

Education

Medical Board Certification

Medical Oncology, American Board of Internal Medicine, 2010

Fellowship

Medical Oncology & Hematology, Johns Hopkins Hospital Sidney Kimmel Comprehensive Cancer Center, 2011

Residency

Internal Medicine, Mayo Clinic College of Medicine and Science, 2008

Degrees

MPH, University of Iowa College of Medicine, 2005
MBBS, All India Institute of Medical Sciences, 2003

Hospital Affiliations

Ronald Reagan UCLA Medical Center

UCLA Santa Monica Medical Center

Research

Interests

Dr. Bardia's research goal is to advance the field of translational oncology and improve clinical outcomes of patients with cancer. He is the principal investigator of several clinical trials investigating precision therapeutics, and he has led the clinical development of novel therapies, including sacituzumab govitecan (IMMU-132), the first ADC approved for patients with metastatic TNBC, elacestrant, the first oral SERD approved for patients with metastatic HR+ breast cancer. Dr. Bardia led the clinical development of blood-based biomarkers, such as CTCs and ctDNA, as "liquid biopsy" for identification of novel targets, therapy selection, monitoring, and understanding resistance to guide therapeutic development.

Publications

  1. Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR, O'Shaughnessy J, Moroose RL, Santin AD, Abramson VG, Shah NC, Rugo HS, Goldenberg DM, Sweidan AM, Iannone R, Washkowitz S, Sharkey RM, Wegener WA, Kalinsky K. Sacituzumab Govitecan hziy in refractory metastatic triplenegative breast cancer. N Engl J Med. 2019 Feb 21;380(8):741-751. PMID: 30786188
  2. Bardia A, Tolaney SM, Hurvitz SA Loirat D, Punie K, Oliveira M, Rugo HS, Brufsky A, Kalinsky K, Cortés J, O'Shaughnessy J, Dieras VC, Carey LA, Gianni L, Piccart M, Loibl S, Goldenberg D, Hong Q, Olivo MS, Itri LM, Rugo H. Sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC). N Engl J Med. 2021 Apr 22;384(16):1529-1541. PMID: 33882206.
  3. Bidard FC, Kaklamani VG, Neven P, Streich G, Montero AJ, Forget F, Mouret- Reynier MA, Sohn JH, Taylor D, Harnden KK, Khong H, Kocsis J, Dalenc F, Dillon PM, Babu S, Waters S, Deleu I, García Sáenz JA, Bria E, Cazzaniga M, Lu J, Aftimos P, Cortés J, Liu S, Tonini G, Laurent D, Habboubi N, Conlan MG, Bardia A. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative advanced breast cancer: Results from the randomized phase III EMERALD trial. J Clin Oncol. 2022 Oct 1;40(28):3246- 3256. PMID: 35584336.
  4. Yu M*, Bardia A*, Wittner BS, Stott SL, Smas ME, Ting DT, Isakoff SJ, Ciciliano JC, Wells MN, Shah AM, Concannon KF, Donaldson MC, Sequist LV, Brachtel E, Sgroi D, Baselga J, Ramaswamy S, Toner M, Haber DA, Maheswaran S. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science. 2013. 339(6119):580-4. *= equal contribution. PMID: 25013076.
  5. Coates JT, Sun S, Leshchiner I, Thimmiah N, Martin EE, McLoughlin D, Danysh BP, Slowik K, Jacobs RA, Rhrissorrakrai K, Utro F, Levovitz C, Denault E, Walmsley CS, Kambadakone A, Stone JR, Isakoff SJ, Parida L, Juric D, Getz G, Bardia A*, Ellisen LW*. Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to Sacituzumab Govitecan in Triplenegative breast cancer. Cancer Discov. 2021 Oct;11(10):2436-2445. . *= equal contribution PMID: 34404686.

Insurance

  • Aetna
  • Anthem Blue Cross
  • Blue Shield of California
  • Centivo
  • Cigna
  • First Health
  • Health Net of California
  • Interplan (part of HealthSmart)
  • Medicare Advantage
  • MultiPlan
  • UFCM Health System
  • Prime Health Services
  • Private Healthcare Systems (PHCS)
  • TRICARE
  • UnitedHealthcare

The list of health care plans above may not be comprehensive and could change. 
Please contact your benefits coordinator or health insurance company directly to verify coverage.

Visit our health insurance information page for more details.

Reviews

Overall Rating:
5.0
40 total ratings | 21 reviews
5.0
May 16, 2025
They were great! Attentive, knowledgeable, compassionate and clear on their recommendations
5.0
May 8, 2025
Dr. Bardia was very sweet, informative, and thorough!!! He answered all my questions and make me feel so informed.
5.0
May 1, 2025
Always a great visit. Detailed, informative and caring.
5.0
April 10, 2025
He clearly explained options, was compassionate about my experience and patient with our discussion.
5.0
March 13, 2025
Dr. Bardia has such incredible bedside manner… he makes me feel at ease and confident about being in his care I feel very blessed to have him as my doctor ❤️